Open Market Insiders Trades
This list includes insiders general transaction with codes filed in Form 4 from SEC:
- P - Open market or private purchase of non-derivative or derivative security
- S - Open market or private sale of non-derivative or derivative security
- V - Transaction voluntarily reported earlier than required
Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
---|---|---|---|---|---|---|
NEM
|
William N Mac Gowan
EVP, Human Resources |
SELL
Open market or private sale
|
Direct | 2,006 Reduced 1.53% |
$70,210
$35.0 p/Share
|
Jun 06
2017 |
NEM
|
E Randall Engel
EVP, Strategic Development |
SELL
Open market or private sale
|
Direct | 5,700 Reduced 2.17% |
$199,500
$35.0 p/Share
|
Jun 06
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 7,274 Reduced 0.31% |
$167,157
$22.98 p/Share
|
Jun 06
2017 |
HBNC
|
James D Neff
President |
SELL
Open market or private sale
|
Direct | 2,829 Reduced 1.88% |
$92,197
$32.59 p/Share
|
Jun 06
2017 |
NP
|
Larry Newton Brownlee
VP & Controller |
SELL
Open market or private sale
|
Direct | 1,450 Reduced 43.13% |
$115,666
$79.77 p/Share
|
Jun 05
2017 |
COST
|
John D Mc Kay
Executive Vice President |
SELL
Open market or private sale
|
Direct | 3,000 Reduced 4.57% |
$544,800
$181.6 p/Share
|
Jun 05
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 4,780 Reduced 0.21% |
$110,466
$23.11 p/Share
|
Jun 05
2017 |
PLXS
|
Dean A Foate
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 2.02% |
$266,650
$53.33 p/Share
|
Jun 05
2017 |
TMO
|
Stephen Williamson
Sr. VP and CFO |
SELL
Open market or private sale
|
Direct | 2,500 Reduced 6.21% |
$440,650
$176.26 p/Share
|
Jun 05
2017 |
UPS
|
Kathleen M. Gutmann
Pres Intl, Healthcare and SCS |
SELL
Open market or private sale
|
Direct | 2,000 Reduced 100.0% |
$214,980
$107.49 p/Share
|
Jun 05
2017 |
SQ
|
James Morgan Mc Kelvey Jr.
Director |
SELL
Open market or private sale
|
Direct | 90,000 Reduced 48.31% |
$2,102,400
$23.36 p/Share
|
Jun 05
2017 |
BX
|
Joan Solotar
SMD, Head of Global PWS |
SELL
Open market or private sale
|
Direct | 30,500 Reduced 16.87% |
$1,015,955
$33.31 p/Share
|
Jun 05
2017 |
INTC
|
Robert Holmes Swan
CEO |
BUY
Open market or private purchase
|
Direct | 13,888 Added 46.91% |
$504,273
$36.31 p/Share
|
Jun 05
2017 |
ACU
|
Brian S Olschan
President and COO |
SELL
Open market or private sale
|
Direct | 687 Reduced 1.71% |
$19,442
$28.3 p/Share
|
Jun 05
2017 |
SPOK
|
Vincent D Kelly
President & CEO |
SELL
Open market or private sale
|
Indirect | 5,000 Reduced 1.4% |
$89,200
$17.84 p/Share
|
Jun 02
2017 |
UNH
|
Gail R Wilensky |
SELL
Open market or private sale
|
Direct | 5,540 Reduced 9.07% |
$990,275
$178.75 p/Share
|
Jun 02
2017 |
AAPL
|
Luca Maestri
Senior Vice President, CFO |
SELL
Open market or private sale
|
Direct | 4,757 Reduced 87.86% |
$735,527
$154.62 p/Share
|
Jun 02
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 14,867 Reduced 0.64% |
$348,928
$23.47 p/Share
|
Jun 02
2017 |
REGN
|
Sanofi |
BUY
Open market or private purchase
|
Indirect | 136,050 Added 0.04% |
$64,709,462
$475.63 p/Share
|
Jun 02
2017 |
ARE
|
James P Cain
Director |
BUY
Open market or private purchase
|
Direct | 100 Added 3.0% |
$11,939
$119.39 p/Share
|
Jun 02
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 10,722 Reduced 0.46% |
$256,149
$23.89 p/Share
|
Jun 01
2017 |
SPOK
|
Vincent D Kelly
President & CEO |
SELL
Open market or private sale
|
Indirect | 5,000 Reduced 1.38% |
$86,900
$17.38 p/Share
|
Jun 01
2017 |
SNX
|
Dennis Polk
Hyve Solutions Executive |
SELL
Open market or private sale
|
Direct | 1,500 Reduced 4.06% |
$167,265
$111.51 p/Share
|
Jun 01
2017 |
SNX
|
Simon Leung
Chief Business Officer |
SELL
Open market or private sale
|
Direct | 144 Reduced 0.55% |
$16,040
$111.39 p/Share
|
Jun 01
2017 |
SNX
|
Simon Leung
Chief Business Officer |
SELL
Open market or private sale
|
Direct | 856 Reduced 3.16% |
$96,172
$112.35 p/Share
|
Jun 01
2017 |
EA
|
Andrew Wilson
Chairman & CEO |
SELL
Open market or private sale
|
Indirect | 8,000 Reduced 1.52% |
$915,760
$114.47 p/Share
|
Jun 01
2017 |
EA
|
Patrick Soderlund
Chief Design Officer |
SELL
Open market or private sale
|
Direct | 8,000 Reduced 4.77% |
$911,680
$113.96 p/Share
|
Jun 01
2017 |
EA
|
Joel Linzner
EVP Worldwide Business Affairs |
SELL
Open market or private sale
|
Direct | 4,000 Reduced 13.29% |
$457,800
$114.45 p/Share
|
Jun 01
2017 |
TMO
|
Marc N Casper
Chairman & CEO |
SELL
Open market or private sale
|
Direct | 20,000 Reduced 6.91% |
$3,455,800
$172.79 p/Share
|
Jun 01
2017 |
QCOM
|
Derek K Aberle
President |
SELL
Open market or private sale
|
Direct | 22,251 Reduced 43.45% |
$1,281,435
$57.59 p/Share
|
Jun 01
2017 |
NEM
|
Gary J Goldberg
Chief Executive Officer |
SELL
Open market or private sale
|
Indirect | 1,000 Reduced 0.66% |
$33,580
$33.58 p/Share
|
Jun 01
2017 |
SNX
|
Dennis Polk
Hyve Solutions Executive |
SELL
Open market or private sale
|
Direct | 427 Reduced 1.26% |
$47,589
$111.45 p/Share
|
Jun 01
2017 |
SNX
|
Dennis Polk
Hyve Solutions Executive |
SELL
Open market or private sale
|
Direct | 2,073 Reduced 5.76% |
$232,943
$112.37 p/Share
|
Jun 01
2017 |
TSLA
|
Kimbal Musk
Director |
SELL
Open market or private sale
|
Direct | 4,691 Reduced 2.79% |
$1,606,527
$342.47 p/Share
|
Jun 01
2017 |
PLXS
|
David J Drury
Director |
SELL
Open market or private sale
|
Direct | 5,000 Reduced 31.25% |
$260,200
$52.04 p/Share
|
Jun 01
2017 |
TZOO
|
Ralph Bartel
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 2,000 Reduced 0.03% |
$21,500
$10.75 p/Share
|
Jun 01
2017 |
NKE
|
Mark G Parker
EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct | 69,300 Reduced 4.47% |
$3,663,891
$52.87 p/Share
|
Jun 01
2017 |
LSXMA
|
Berkshire Hathaway Inc |
BUY
Open market or private purchase
|
Indirect | 226,014 Added 0.72% |
$9,361,499
$41.42 p/Share
|
May 31
2017 |
LSXMA
|
Berkshire Hathaway Inc |
BUY
Open market or private purchase
|
Indirect | 110,146 Added 0.74% |
$4,569,958
$41.49 p/Share
|
May 31
2017 |
ADI
|
Vincent Roche
Chair & CEO |
SELL
Open market or private sale
|
Direct | 23,750 Reduced 35.43% |
$2,113,512
$88.99 p/Share
|
May 31
2017 |
ALNY
|
Sanofi
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 297,501 Added 2.74% |
$21,381,398
$71.87 p/Share
|
May 31
2017 |
INTU
|
Henry Tayloe Stansbury
EVP, Chief Technology Officer |
SELL
Open market or private sale
|
Direct | 39,230 Reduced 97.91% |
$5,502,008
$140.25 p/Share
|
May 31
2017 |
FCAP
|
Pamela G Kraft
Director |
BUY
Open market or private purchase
|
Direct | 150 Added 13.62% |
$4,769
$31.79 p/Share
|
May 31
2017 |
SQ
|
Lawrence Henry Summers
Director |
SELL
Open market or private sale
|
Indirect | 100,000 Reduced 100.0% |
$2,322,000
$23.22 p/Share
|
May 31
2017 |
RARX
|
Novartis Bioventures LTD
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 35,539 Reduced 1.49% |
$850,804
$23.94 p/Share
|
May 31
2017 |
AMGN
|
David Baltimore
Director |
SELL
Open market or private sale
|
Direct | 3,700 Reduced 10.61% |
$569,541
$153.93 p/Share
|
May 31
2017 |
MS
|
Mitsubishi Ufj Financial Group Inc
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 0 Added 0.0% |
$0
$41.74 p/Share
|
May 31
2017 |
TZOO
|
Ralph Bartel 2005 Trust
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 15,075 Reduced 0.2% |
$160,549
$10.65 p/Share
|
May 30
2017 |
TZOO
|
Ralph Bartel
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 15,075 Reduced 0.2% |
$160,549
$10.65 p/Share
|
May 30
2017 |
TZOO
|
Azzurro Capital Inc
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 15,075 Reduced 0.2% |
$160,549
$10.65 p/Share
|
May 30
2017 |